BERLIN & NASHVILLE, Tenn.--(BUSINESS WIRE)--Bayer and Vanderbilt University Medical Center (VUMC) today announced that they have entered a strategic five-year collaboration agreement to advance innovative therapies from target identification through Investigational New Drug (IND) application. The agreement spans across all indications currently pursued by Bayer, initially focusing on cardiovascular and kidney diseases, two therapeutic areas with significant unmet medical need. The collaboration. ...